

# Hagit Eldar-Finkelman

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6444381/hagit-eldar-finkelman-publications-by-year.pdf>

**Version:** 2023-06-01

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

57  
papers

7,147  
citations

33  
h-index

58  
g-index

58  
ext. papers

7,908  
ext. citations

5.6  
avg, IF

5.43  
L-index

#	Paper	IF	Citations
57	GSK-3 Inhibition in Birds Affects Social Behavior and Increases Motor Activity.. <i>Frontiers in Physiology</i> , <b>2022</b> , 13, 881174	4.4	
56	Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration. <i>Cells</i> , <b>2021</b> , 10,	7.6	13
55	Inhibition of GSK-3 ameliorates the pathogenesis of Huntington's disease. <i>Neurobiology of Disease</i> , <b>2021</b> , 154, 105336	7.2	4
54	Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward.. <i>Frontiers in Molecular Neuroscience</i> , <b>2021</b> , 14, 792364	5.9	5
53	Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.1	9
52	GSK-3-TSC axis governs lysosomal acidification through autophagy and endocytic pathways. <i>Cellular Signalling</i> , <b>2020</b> , 71, 109597	4.8	11
51	Novel Modality of GSK-3 Inhibition For Treating Neurodegeneration. <i>Journal of Neurology and Neuromedicine</i> , <b>2018</b> , 3, 5-7	0.4	1
50	Up-regulation of insulin-like growth factor 2 by ketamine requires glycogen synthase kinase-3 inhibition. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2017</b> , 72, 49-54	5.4	13
49	Ketamine up-regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen synthase kinase-3. <i>World Journal of Biological Psychiatry</i> , <b>2017</b> , 18, 445-456	3.7	9
48	Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice. <i>JCI Insight</i> , <b>2017</b> , 2, e91782	9.6	17
47	A unique type of GSK-3 inhibitor brings new opportunities to the clinic. <i>Science Signaling</i> , <b>2016</b> , 9, ra110	8.5	47
46	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , <b>2016</b> , 12, 1-222	9.9	3816
45	Science Signaling Podcast for 15 November 2016: A new type of kinase inhibitor. <i>Science Signaling</i> , <b>2016</b> , 9, c22	8.5	1
44	GSK-3 Inhibition Affects Singing Behavior and Neurogenesis in Adult Songbirds. <i>Brain, Behavior and Evolution</i> , <b>2015</b> , 85, 233-44	1.4	5
43	Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth. <i>Oncogene</i> , <b>2015</b> , 34, 4613-23	8.9	63
42	Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3 inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>2013</b> , 56, 10066-78	7.9	30
41	GSK-3 inhibition: achieving moderate efficacy with high selectivity. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , <b>2013</b> , 1834, 1410-4	3.8	32

40	Inhibition of glycogen synthase kinase-3 ameliorates $\beta$ amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 1295-306	5	155
39	Structure-based optimization of oxadiazole-based GSK-3 inhibitors. <i>European Journal of Medicinal Chemistry</i> , <b>2013</b> , 61, 26-40	6.5	28
38	Regulation of Th1 cells and experimental autoimmune encephalomyelitis by glycogen synthase kinase-3. <i>Journal of Immunology</i> , <b>2013</b> , 190, 5000-11	5.2	55
37	GSK-3 and lysosomes meet in Alzheimer's disease. <i>Communicative and Integrative Biology</i> , <b>2013</b> , 6, e251796	6	6
36	Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3. <i>Journal of Medicinal Chemistry</i> , <b>2012</b> , 55, 4407-24	7.9	37
35	Exploiting substrate recognition for selective inhibition of protein kinases. <i>Current Pharmaceutical Design</i> , <b>2012</b> , 18, 2914-20	3.1	10
34	Wnt signaling pathway overcomes the disruption of neuronal differentiation of neural progenitor cells induced by oligomeric amyloid $\beta$ peptide. <i>Journal of Neurochemistry</i> , <b>2011</b> , 116, 522-9	5.8	37
33	Selective loss of glycogen synthase kinase-3 in birds reveals distinct roles for GSK-3 isozymes in tau phosphorylation. <i>FEBS Letters</i> , <b>2011</b> , 585, 1158-62	3.6	31
32	Synthesis and biological evaluation of glycogen synthase kinase 3 (GSK-3) inhibitors: an fast and atom efficient access to 1-aryl-3-benzylureas. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2011</b> , 21, 5610-5 <sup>8</sup>	3.8	17
31	Distinct molecular regulation of glycogen synthase kinase-3alpha isozyme controlled by its N-terminal region: functional role in calcium/calpain signaling. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 13470-80	5	32
30	GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. <i>Frontiers in Molecular Neuroscience</i> , <b>2011</b> , 4, 32	5.9	222
29	Elucidating substrate and inhibitor binding sites on the surface of GSK-3 and the refinement of a competitive inhibitor. <i>Journal of Molecular Biology</i> , <b>2011</b> , 408, 366-78	6.3	19
28	Identification of eukaryotic elongation factor-2 as a novel cellular target of lithium and glycogen synthase kinase-3. <i>Molecular and Cellular Neurosciences</i> , <b>2010</b> , 45, 449-55	4.6	17
27	GSK3beta and beta-catenin modulate radiation cytotoxicity in pancreatic cancer. <i>Neoplasia</i> , <b>2010</b> , 12, 357-65	6.1	39
26	Substrate competitive GSK-3 inhibitors - strategy and implications. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , <b>2010</b> , 1804, 598-603	3.8	39
25	Glycogen synthase kinase 3 beta mediates high glucose-induced ubiquitination and proteasome degradation of insulin receptor substrate 1. <i>Journal of Endocrinology</i> , <b>2010</b> , 206, 171-81	4.6	55
24	Peptide inhibitors targeting protein kinases. <i>Current Pharmaceutical Design</i> , <b>2009</b> , 15, 2463-70	3.1	64
23	Nuclear GSK-3beta inhibits the canonical Wnt signalling pathway in a beta-catenin phosphorylation-independent manner. <i>Oncogene</i> , <b>2008</b> , 27, 3546-55	8.9	72

22	New insights into the autoinhibition mechanism of glycogen synthase kinase-3beta. <i>Journal of Molecular Biology</i> , <b>2008</b> , 383, 999-1007	6.3	18
21	Coordinated phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 and protein kinase C beta1 in the diabetic fat tissue. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2008</b> , 294, E1169-77	5.7	22
20	Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role in hepatic insulin signaling. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2008</b> , 294, E307-15	5.7	50
19	The SIL gene is essential for mitotic entry and survival of cancer cells. <i>Cancer Research</i> , <b>2007</b> , 67, 4022-7	9.6	33
18	Role of glycogen synthase kinase-3beta in early depressive behavior induced by mild traumatic brain injury. <i>Molecular and Cellular Neurosciences</i> , <b>2007</b> , 34, 571-7	4.6	91
17	Identification of novel glycogen synthase kinase-3beta substrate-interacting residues suggests a common mechanism for substrate recognition. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 30621-30	5	38
16	Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2006</b> , 316, 17-24	4.5	98
15	Peptides targeting protein kinases: strategies and implications. <i>Physiology</i> , <b>2006</b> , 21, 411-8	9.4	35
14	Serine 332 phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 attenuates insulin signaling. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 4422-8	5	122
13	PKC-delta-dependent activation of oxidative stress in adipocytes of obese and insulin-resistant mice: role for NADPH oxidase. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2005</b> , 288, E405-11	5.7	91
12	Lithium-mediated phosphorylation of glycogen synthase kinase-3beta involves PI3 kinase-dependent activation of protein kinase C-alpha. <i>Journal of Molecular Neuroscience</i> , <b>2004</b> , 24, 237-45	4.2	53
11	Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. <i>Biological Psychiatry</i> , <b>2004</b> , 55, 781-4	1.9	238
10	Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment. <i>Expert Opinion on Investigational Drugs</i> , <b>2003</b> , 12, 1511-9	5.7	38
9	Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2003</b> , 305, 974-80	4.5	129
8	Increased glucose uptake promotes oxidative stress and PKC-delta activation in adipocytes of obese, insulin-resistant mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2003</b> , 285, E295-302	5.7	133
7	Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: insight into the insulin-mimetic action of zinc. <i>Biochemical and Biophysical Research Communications</i> , <b>2002</b> , 295, 102-6	3.3	122
6	Glycogen synthase kinase 3: an emerging therapeutic target. <i>Trends in Molecular Medicine</i> , <b>2002</b> , 8, 126-32	11.1	331
5	The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. <i>Expert Opinion on Therapeutic Targets</i> , <b>2002</b> , 6, 555-61	6.2	79

4	Monitor and Molecules. <i>Drug Discovery Today</i> , <b>2001</b> , 6, 1072-1073	8.4	1
3	Leptin induces insulin-like signaling that antagonizes cAMP elevation by glucagon in hepatocytes. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 11348-54	5	182
2	Regulation of ribosomal S6 protein kinase-p90(rsk), glycogen synthase kinase 3, and beta-catenin in early <i>Xenopus</i> development. <i>Molecular and Cellular Biology</i> , <b>1999</b> , 19, 1427-37	4.6	46
1	Inactivation of glycogen synthase kinase-3 by epidermal growth factor is mediated by mitogen-activated protein kinase/p90 ribosomal protein S6 kinase signaling pathway in NIH/3T3 cells. <i>Journal of Biological Chemistry</i> , <b>1995</b> , 270, 987-90	5	182